Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Related GWPH
3 Pharma Companies Investing In Cannabis-Related Treatments
Insys, GW Pharmaceuticals Rise On Short Seller's Comments

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings

 

Related Articles (GWPH)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters